Drugs Containing Excipient (Inactive Ingredient) OLEIC ACID

« Back to Dashboard

Branded drugs containing OLEIC ACID excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia and Upjohn Company LLC	DETROL LA	tolterodine tartrate	0009-5190	OLEIC ACID
Merck Sharp & Dohme Corp	PROVENTIL HFA	albuterol sulfate	0085-1132	OLEIC ACID
Merck Sharp & Dohme Corp	ASMANEX HFA	mometasone furoate	0085-4333	OLEIC ACID
Merck Sharp & Dohme Corp	DULERA	mometasone furoate and formoterol fumarate dihydrate	0085-7206	OLEIC ACID	1969-12-31
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1207	OLEIC ACID
Allergan Inc	NAMZARIC	memantine hydrochloride and donepezil hydrochloride	0456-1214	OLEIC ACID

Generic drugs containing OLEIC ACID excipient

Company	Ingredient	NDC	Excipient
Pharmacia and Upjohn Company LLC	tolterodine tartrate	0009-5190	OLEIC ACID
Hikma Pharmaceuticals USA Inc	albuterol sulfate	0054-0742	OLEIC ACID
Merck Sharp & Dohme Corp	albuterol sulfate	0085-1132	OLEIC ACID
Merck Sharp & Dohme Corp	mometasone furoate	0085-4333	OLEIC ACID
Merck Sharp & Dohme Corp	mometasone furoate and formoterol fumarate dihydrate	0085-7206	OLEIC ACID
E Fougera & Co a division of Fougera Pharmaceuticals Inc	imiquimod	0168-0432	OLEIC ACID

Oleic Acid Pharmaceutical Excipient Market: Dynamics, Financial Trajectory, Regulation, and Patent Risk

Last updated: September 2, 2026

Oleic acid is a mature, low-cost lipid excipient with demand tied to oral lipid formulations, softgels, topical products, lipid nanoparticles, and pharmaceutical-grade emulsions. Its financial trajectory is driven less by proprietary pricing than by feedstock costs, purification requirements, regional supply, and growth in lipid-based drug delivery. Commodity-grade oleic acid is widely available, while pharmaceutical-grade material commands a premium because of tighter identity, purity, oxidation, residual-solvent, and traceability controls.

The global oleic acid market is commonly estimated in the multibillion-dollar range across food, personal care, industrial, and pharmaceutical applications. Pharmaceutical use is a small share of total volume but has higher margins and stronger qualification barriers. Public companies generally do not report pharmaceutical-grade oleic acid revenue separately, so standalone financial projections are modeled from broader oleochemical and excipient markets rather than audited segment disclosures.

What is oleic acid and how is it used as a pharmaceutical excipient?

Oleic acid is a monounsaturated C18 fatty acid with the chemical name cis-9-octadecenoic acid and CAS Registry Number 112-80-1. It is usually produced from vegetable oils or animal-derived fats and supplied as a purified fatty-acid fraction.

Attribute	Pharmaceutical relevance
Chemical formula	C18H34O2
Molecular weight	282.47 g/mol
Physical form	Oily liquid at ambient temperature
Primary function	Solubilizer, wetting agent, penetration enhancer, lipid vehicle, emulsifier component
Common formulation context	Softgels, self-emulsifying drug-delivery systems, topical products, emulsions, lipid nanoparticles
Main quality risk	Oxidation and variation in fatty-acid composition
Regulatory category	Inactive ingredient when used in approved drug products
Orange Book status	No standalone Orange Book listing as an excipient

Oleic acid improves the apparent solubility of poorly water-soluble active pharmaceutical ingredients and can support self-emulsifying drug-delivery systems. In topical formulations, it can increase skin permeability by altering lipid organization in the stratum corneum. In lipid nanoparticles and related systems, oleic acid or oleate derivatives can influence particle structure, surface charge, encapsulation, and cellular interaction.

Its performance depends on more than nominal oleic acid content. Peroxide value, acid value, iodine value, moisture, color, odor, residual solvents, heavy metals, and the profile of linoleic, palmitic, stearic, and other fatty acids affect formulation behavior.

How large is the pharmaceutical-grade oleic acid market?

The pharmaceutical-grade segment is substantially smaller than the total oleic acid market. Published commercial estimates usually combine food, cosmetics, industrial chemicals, animal nutrition, and pharmaceutical uses. Those reports generally place the overall oleic acid market at several billion dollars, with mid-single-digit annual growth projected through the late 2020s.[1][2]

A practical market model is:

Market layer	Indicative position
Total oleic acid market	Multibillion-dollar global market
Pharmaceutical and medical applications	Low-single-digit share of total volume
Pharmaceutical-grade value share	Higher than volume share because of qualification and testing
Growth profile	Mid-single-digit annual growth in the broader market
Principal demand driver	Lipid-based delivery and specialty formulations
Principal margin constraint	Commodity substitution and feedstock volatility

The pharmaceutical segment benefits from the expansion of poorly soluble drug pipelines, oral lipid formulations, topical delivery systems, and nanomedicine. Demand is also supported by increased use of excipients with established compendial histories, since formulation developers often prefer materials with recognized quality standards and prior regulatory use.

The market does not have the pricing profile of a protected active pharmaceutical ingredient. Buyers can often qualify multiple suppliers, and the underlying molecule is widely available. Pharmaceutical-grade supply therefore earns value through documentation, consistency, validated processing, and regulatory support.

What is the financial trajectory for oleic acid excipient suppliers?

Oleic acid suppliers are likely to experience revenue growth from volume expansion, but margin performance will remain exposed to agricultural and oleochemical cycles.

Revenue drivers

The main revenue drivers are:

1. Growth in lipid-based drug-delivery systems.
2. Increased use of self-emulsifying formulations for poorly soluble APIs.
3. Expansion of topical and transdermal delivery products.
4. Demand for high-purity excipients in regulated markets.
5. Increased use of lipid materials in nanoparticles and injectable research platforms.
6. Outsourcing of excipient qualification and supply-chain management to specialty distributors.

Margin drivers

Pharmaceutical-grade oleic acid can generate a premium over industrial material, but the premium depends on specification. Suppliers with low peroxide values, narrow composition ranges, validated purification, and robust stability data can obtain stronger pricing than producers selling only on oleic-acid assay.

Margins are pressured by:

• Vegetable-oil and tallow feedstock prices.
• Energy and hydrogenation costs.
• Freight and storage costs.
• Oxidation-related waste.
• Customer-specific testing.
• Dual sourcing requirements.
• Competition from medium-chain triglycerides, oleates, phospholipids, and synthetic surfactants.

Feedstock integration is commercially important. Producers that control refining, fractionation, blending, and packaging can preserve margins better than distributors that purchase bulk oleic acid and resell it into regulated markets.

Financial outlook by period

Period	Expected market condition	Financial implication
2024-2026	Stable base demand with continued lipid-delivery development	Moderate revenue growth; volatile gross margins
2027-2029	Broader adoption of specialty lipid systems and nanomedicine inputs	Higher pharmaceutical-grade demand
2030 onward	More differentiated excipient specifications and regional qualification	Premium for validated, traceable, low-oxidation material

The strongest financial upside is not likely to come from bulk oleic acid alone. It is more likely to arise from higher-value grades, custom blends, prequalified excipient systems, and formulation services built around lipid delivery.

Which pharmaceutical formulations use oleic acid?

Oral lipid formulations

Oleic acid is used in lipid vehicles and self-emulsifying drug-delivery systems. These systems can improve dissolution and absorption for lipophilic APIs. Oleic acid is often combined with surfactants, cosolvents, medium-chain or long-chain glycerides, and triglycerides.

The commercial value is highest where the excipient is part of a validated formulation platform rather than a replaceable bulk ingredient.

Softgel and capsule formulations

Oleic acid and related lipid materials can be used in liquid-filled capsules and softgel systems. The formulation must address oxidation, capsule compatibility, fill viscosity, and interaction with gelatin or other shell materials.

Topical and transdermal formulations

Oleic acid is used as a penetration enhancer and emollient. Its effect is concentration-dependent and formulation-specific. Excessive levels can cause irritation, instability, or undesirable changes in skin barrier function.

Emulsions and lipid nanoparticles

Oleic acid can act as a hydrophobic component, co-emulsifier, or surface-modifying lipid. In nanoparticle systems, the grade and oxidation profile can affect particle size, encapsulation, release, and storage stability.

Oleate salts and derivatives

Sodium oleate and other oleate-based materials are separate substances with distinct specifications and regulatory treatment. They may be used as surfactants, emulsifying agents, or formulation intermediates. A supplier cannot assume that qualification of oleic acid automatically qualifies an oleate salt.

What FDA regulatory status applies to oleic acid?

Oleic acid is used as an inactive ingredient in drug products, subject to the requirements applicable to the finished dosage form and route of administration. The FDA Inactive Ingredient Database is the principal public reference for prior use in approved drug products.[3]

FDA status depends on:

• The specific chemical form.
• Route of administration.
• Maximum daily exposure or concentration.
• Dosage form.
• Quality grade.
• Manufacturing controls.
• Use in the proposed formulation.

The presence of oleic acid in the Inactive Ingredient Database does not create a blanket approval for every route, concentration, or product type. A new use may require additional justification, toxicology, compatibility data, and route-specific review.

Oleic acid is also covered by pharmacopeial and food-ingredient frameworks in relevant jurisdictions. The United States Pharmacopeia-National Formulary and European Pharmacopoeia provide quality standards for applicable materials.[4][5] Food and cosmetic acceptance does not replace pharmaceutical excipient qualification.

What is the Orange Book status of oleic acid?

Oleic acid has no standalone Orange Book listing because it is an excipient, not an approved active ingredient with independent therapeutic claims.[6]

The Orange Book identifies approved drug products, active ingredients, dosage forms, routes, therapeutic equivalence evaluations, and listed patents or exclusivity information for qualifying products. It does not create a patent or exclusivity right for a conventional excipient used in those products.

What patents protect pharmaceutical oleic acid formulations?

The oleic acid molecule is old and widely known. Basic composition patents are not a meaningful source of exclusivity for pharmaceutical-grade oleic acid.

Patent protection may instead attach to:

• A specific drug-plus-oleic-acid formulation.
• A self-emulsifying composition with defined ratios.
• A topical formulation with a penetration-enhancing effect.
• A lipid nanoparticle composition.
• A particle-size or manufacturing process.
• A method of treating a disease using a formulation containing oleic acid.
• A capsule, container, or delivery device.
• A defined impurity or oxidation-control process.

The enforceability of these rights depends on claim construction, written description, enablement, prior art, prosecution history, and jurisdiction. A patent that names oleic acid in a long Markush list does not necessarily create meaningful blocking risk for a supplier selling the excipient.

Patent and litigation profile

Issue	Assessment
Composition-of-matter patent on oleic acid	No commercially meaningful current exclusivity
Excipient-only patent estate	Generally weak
Formulation patent risk	Potentially material for narrow drug products
Method-of-use patent risk	Product- and indication-specific
Manufacturing patent risk	Possible for purification, oxidation control, or specialty grades
Orange Book listing	No standalone listing
Paragraph IV exposure	Not applicable to oleic acid as an excipient
Biosimilar risk	Not applicable
Supplier freedom to operate	Usually broad for the molecule; narrower for proprietary formulations

Are there Paragraph IV challenges or generic-entry risks for oleic acid?

There are no Paragraph IV challenges directed at oleic acid as an excipient. Paragraph IV certifications apply to patents listed for an approved reference drug in the FDA Orange Book, not to a commodity excipient sold independently.

Generic-entry risk arises indirectly when oleic acid is part of a drug product. A generic applicant may challenge patents covering:

• The active ingredient.
• The dosage form.
• The formulation.
• The method of treatment.
• The manufacturing process.
• The drug’s pharmacokinetic profile.

Oleic acid can therefore appear in the technical facts of a Paragraph IV dispute without being the target of the certification. The commercial effect depends on whether the formulation patent claims require oleic acid specifically or permit substitution with another lipid.

What manufacturing and intellectual-property barriers affect supply?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Pharmaceutical customers typically assess:

• Source and botanical or animal origin.
• Batch-to-batch fatty-acid profile.
• Peroxide and anisidine values.
• Acid value and iodine value.
• Residual solvents and contaminants.
• Microbial quality where relevant.
• Packaging and oxygen exposure.
• Retest period and stability data.
• Change-control procedures.
• GMP compliance and audit history.

Oxidation is a central technical risk. Oleic acid is more oxidation-resistant than polyunsaturated fatty acids but is not oxidation-proof. Nitrogen blanketing, antioxidant strategy, light control, low-oxygen packaging, and temperature management can affect shelf life and product performance.

Intellectual-property barriers

IP barriers are more likely to arise from customer formulations than from oleic acid production. A supplier may need to analyze whether its purification process, blend, particle size, or delivery system practices a third-party claim. Contractual restrictions, customer specifications, and proprietary analytical methods can be more commercially significant than patents.

Which companies compete in the pharmaceutical-grade oleic acid market?

The market includes oleochemical producers, specialty excipient suppliers, and distributors. Competition is fragmented because the same companies often sell multiple grades into food, cosmetics, industrial chemicals, and pharmaceuticals.

Relevant supplier groups include:

• Large oleochemical producers with integrated vegetable-oil or tallow feedstocks.
• Specialty lipid and excipient suppliers.
• Pharmacopeial-grade distributors.
• Custom formulation and lipid-delivery companies.
• Regional manufacturers serving Asia-Pacific, Europe, and North America.

Major oleochemical companies such as KLK OLEO, Emery Oleochemicals, Wilmar International, IOI Oleochemical, and Croda have capabilities relevant to fatty-acid production, specialty lipids, or pharmaceutical supply chains, although public disclosures do not consistently identify standalone pharmaceutical-grade oleic acid revenue.[7][8][9]

The competitive advantage is strongest for suppliers that provide global regulatory files, consistent lot quality, multiple manufacturing sites, and validated packaging. Lowest-cost bulk production is less decisive once a drug developer has completed supplier qualification.

How does oleic acid compare with competing pharmaceutical excipients?

Excipient	Relative strength	Main limitation
Oleic acid	Low cost, established lipid chemistry, useful penetration and solubilization properties	Oxidation, odor, composition variability
Medium-chain triglycerides	Good oral lipid vehicle and oxidation profile	Different solubilization and digestion behavior
Caprylic/capric triglyceride	Stable and widely used in lipid systems	May not reproduce oleic-acid permeability effects
Phospholipids	Strong biological compatibility and nanoparticle utility	Higher cost and more complex sourcing
Polysorbates	Broad emulsification utility	Peroxide formation and degradation concerns
Labrasol-type excipients	Strong self-emulsifying performance	Proprietary grades and higher cost
Isopropyl myristate	Effective topical vehicle and penetration enhancer	Limited suitability for oral or injectable use

Oleic acid competes effectively where cost and established formulation behavior matter. It is less attractive when oxidation control, injectable compatibility, or highly reproducible nanoparticle architecture is the primary requirement.

What geographic trends shape oleic acid demand?

Asia-Pacific is the central production and consumption region for oleochemicals because of palm, palm-kernel, soybean, and other vegetable-oil supply chains. China and India contribute substantial pharmaceutical formulation demand, while Europe and North America impose stringent documentation, sustainability, and quality requirements.

Regional commercial considerations include:

• Palm-derived supply and sustainability certification.
• Animal-origin restrictions.
• European REACH and pharmaceutical quality requirements.
• U.S. FDA supplier qualification.
• Freight exposure for bulk liquids.
• Local inventory requirements for critical excipients.
• Dual sourcing after pandemic-era supply disruptions.

Geographic diversification has value because a single agricultural region can affect feedstock availability and pricing across the global market.

What revenue exposure do pharmaceutical companies have to oleic acid supply?

For most finished-dose drug companies, direct revenue exposure to oleic acid pricing is low. Oleic acid often represents a small fraction of total cost of goods sold. The larger exposure is operational:

• A qualified-source failure can delay batch release.
• A specification change can trigger reformulation or comparability work.
• Oxidation can reduce stability or cause product complaints.
• A shortage can interrupt softgel, topical, or lipid-nanoparticle production.
• A formulation-specific patent can constrain substitution.

For excipient suppliers, revenue exposure is greater because pharmaceutical-grade sales depend on long-term customer qualification. The key metric is not bulk tonnage alone. It is the number of qualified pharmaceutical customers, recurring orders, approved manufacturing sites, and products that incorporate the supplier’s grade.

When does oleic acid lose exclusivity?

Oleic acid has no relevant modern pharmaceutical exclusivity period to lose. The molecule and its general uses have been known for decades, and the excipient is not protected by a current standalone patent monopoly.

Exclusivity can still exist around a finished drug product or delivery platform. Those rights expire according to the specific formulation, method-of-use, manufacturing, or device patents involved. They do not prevent other companies from manufacturing or selling oleic acid outside the claimed product or process.

Key Takeaways

• Oleic acid is a mature excipient and commodity lipid with no standalone pharmaceutical exclusivity.
• Pharmaceutical-grade demand should grow faster than basic industrial demand because of lipid-based delivery, softgels, topical products, and nanomedicine.
• Public companies do not generally disclose pharmaceutical oleic acid revenue separately.
• Pricing is driven by feedstock, purification, oxidation control, documentation, and supply reliability.
• FDA and pharmacopeial recognition supports use but does not approve every route, concentration, or dosage form.
• There is no standalone Orange Book listing and no Paragraph IV or biosimilar pathway directed at oleic acid.
• Patent risk is concentrated in drug formulations, methods of use, lipid nanoparticles, and manufacturing processes.
• The strongest supplier positions will come from qualified pharmaceutical grades, regulatory support, stable global supply, and customer-specific lipid systems.

FAQs About Pharmaceutical-Grade Oleic Acid

Is oleic acid listed in the FDA Inactive Ingredient Database?

Oleic acid has prior use as an inactive ingredient in approved drug products. The applicable route, dosage form, and exposure limits must be assessed in the FDA Inactive Ingredient Database for the proposed product.[3]

Is pharmaceutical-grade oleic acid suitable for injectable products?

Suitability is product-specific. Injectable use requires route-specific toxicology, sterility or bioburden controls, endotoxin assessment where applicable, compatibility data, and regulatory justification. General pharmaceutical or cosmetic grade is not automatically suitable for injection.

Does oleic acid improve oral bioavailability?

It can improve dissolution and absorption for certain poorly water-soluble APIs when incorporated into an appropriate lipid formulation. The effect depends on drug chemistry, formulation composition, digestion, precipitation, and intestinal absorption.

Can pharmaceutical companies substitute medium-chain triglycerides for oleic acid?

Substitution requires formulation development and comparability testing. Medium-chain triglycerides may differ in solubilization, digestion, permeability, viscosity, oxidation profile, and drug-release behavior.

What is the main quality specification for pharmaceutical oleic acid?

No single specification controls all applications. Typical controls include oleic-acid assay, fatty-acid composition, acid value, iodine value, peroxide value, moisture, impurities, residual solvents, color, and stability data. The required profile is defined by the applicable monograph and finished-product formulation.

References

1. Grand View Research. (2024). Oleic acid market size, share and trends analysis report. https://www.grandviewresearch.com/industry-analysis/oleic-acid-market

2. Mordor Intelligence. (2024). Oleic acid market size and share analysis: Growth trends and forecasts. https://www.mordorintelligence.com/industry-reports/oleic-acid-market

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. https://www.uspnf.com

5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. https://www.edqm.eu/en/european-pharmacopoeia-ph-eur-11th-edition

6. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

7. Kuala Lumpur Kepong Berhad. (2024). Annual report 2024. https://www.klk.com.my

8. Croda International Plc. (2024). Annual report and accounts 2024. https://www.croda.com/en-gb/investors/results-and-reports

9. Wilmar International Limited. (2024). Annual report 2024. https://www.wilmar-international.com/investors/annual-reports